{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:23:41Z","timestamp":1794590621829,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":2189,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1111\/j.1469-0691.2008.02124.x","type":"journal-article","created":{"date-parts":[[2008,11,21]],"date-time":"2008-11-21T06:07:46Z","timestamp":1227247666000},"page":"19-29","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S6","title":["What's new and not so new on the antimicrobial horizon?"],"prefix":"10.1016","volume":"14","author":[{"given":"G.L.","family":"French","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2008.02124.x_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0140-6736(59)90383-6","article-title":"Epidemic staphylococci","volume":"1","author":"Williams","year":"1959","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2008.02124.x_bib2","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1093\/clinids\/24.Supplement_1.S67","article-title":"Trends in bacterial resistance to fluoroquinolones","volume":"24","author":"Acar","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1128\/AAC.42.5.1303","article-title":"Historical yearly usage of vancomycin","volume":"42","author":"Kirst","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib4","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(00)04376-2","article-title":"Infections due to vancomycin\u2010resistant Enterococcus faecium resistant to linezolid","volume":"357","author":"Gonzales","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib5","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1001\/jama.1959.63010180008012","article-title":"Occurrence of serious bacterial infections since introduction of antibacterial agents","volume":"170","author":"Finland","year":"1959","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMp048093","article-title":"The antibiotic pipeline\u2014challenges, costs, and values","volume":"351","author":"Wenzel","year":"2004","journal-title":"N Engl J Med"},{"issue":"4 suppl","key":"10.1111\/j.1469-0691.2008.02124.x_bib7","doi-asserted-by":"crossref","first-page":"N64","DOI":"10.1097\/00003246-200104001-00002","article-title":"Increasing prevalence of antimicrobial resistance in intensive care units","volume":"29","author":"Fridkin","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-134-4-200102200-00014","article-title":"Antibiotic resistance in the intensive care unit","volume":"134","author":"Kollef","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib9","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1126\/science.257.5073.1050","article-title":"Epidemiology of drug resistance: implications for a post\u2010antimicrobial era","volume":"257","author":"Cohen","year":"1992","journal-title":"Science"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-118-7-199304010-00011","article-title":"Resistance to antimicrobial drugs\u2014a worldwide calamity","volume":"118","author":"Kunin","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1126\/science.257.5073.1064","article-title":"The crisis in antibiotic resistance","volume":"257","author":"Neu","year":"1992","journal-title":"Science"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2008.02124.x_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1465-0691.2004.1004.x","article-title":"The need for new antibiotics","volume":"10","author":"Livermore","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1473-3099(05)70086-4","article-title":"Lack of development of new antimicrobial drugs: a potential serious threat to public health","volume":"5","author":"Norrby","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1086\/420937","article-title":"Trends in antimicrobial drug development: implications for the future","volume":"38","author":"Spellberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3201\/eid1202.050078","article-title":"Antimicrobial drug resistance, regulation, and research","volume":"12","author":"Metlay","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/jac\/dkl138","article-title":"Antimicrobial resistance: paradox, actions and economics","volume":"57","author":"Wise","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib17","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","article-title":"Activities of doripenem (S\u20104661) against drug\u2010resistant clinical pathogens","volume":"48","author":"Jones","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib18","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1128\/AAC.48.7.2576-2580.2004","article-title":"Multiple\u2010dose pharmacokinetics and safety of a novel broad\u2010spectrum cephalosporin (BAL5788) in healthy volunteers","volume":"48","author":"Schmitt\u2010Hoffmann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib19","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.bmcl.2003.07.023","article-title":"Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria","volume":"13","author":"Schneider","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkf249","article-title":"In\u00a0vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin\u2010resistant staphylococci","volume":"50","author":"Jones","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib21","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1128\/AAC.49.10.4210-4219.2005","article-title":"Antistaphylococcal activity of ceftobiprole, a new broad\u2010spectrum cephalosporin","volume":"49","author":"Bogdanovich","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/AAC.46.3.872-875.2002","article-title":"In\u00a0vitro activities of BAL9141, a novel broad\u2010spectrum pyrrolidinone cephalosporin, against gram\u2010negative nonfermenters","volume":"46","author":"Zbinden","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/49.3.535","article-title":"BAL\u00a09141, a new broad\u2010spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials","volume":"49","author":"Wootton","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double\u2010blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram\u2010positive bacteria","volume":"55","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib25","doi-asserted-by":"crossref","unstructured":"Doripenem: S\u00a04661. Drugs R D. 2003;4:363\u2013365.","DOI":"10.2165\/00126839-200304060-00006"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against Gram\u2010negative bacilli with various beta\u2010lactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14787210.5.5.793","article-title":"Carbapenems in the USA: focus on doripenem","volume":"5","author":"Lister","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S\u20104661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib29","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/13543784.16.9.1441","article-title":"Iclaprim","volume":"16","author":"Kohlhoff","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2008.02124.x_bib30","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1128\/AAC.48.5.1885-1886.2004","article-title":"In\u00a0vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C.\u00a0pneumoniae","volume":"48","author":"Kohlhoff","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14612611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14612611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T12:29:32Z","timestamp":1557923372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14612611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":30,"alternative-id":["S1198743X14612611"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02124.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}